UK markets close in 2 hours 38 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
150.90+1.28 (+0.86%)
At close: 04:00PM EDT
149.86 -1.04 (-0.69%)
After hours: 04:04PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 19.09B
Enterprise value 18.02B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.45
Price/book (mrq)N/A
Enterprise value/revenue 8.99
Enterprise value/EBITDA -25.65

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-18.87%
S&P500 52-week change 327.84%
52-week high 3218.88
52-week low 3141.98
50-day moving average 3149.36
200-day moving average 3168.63

Share statistics

Avg vol (3-month) 3577.23k
Avg vol (10-day) 3488.98k
Shares outstanding 5126.49M
Implied shares outstanding 6127.02M
Float 8125.96M
% held by insiders 10.41%
% held by institutions 192.55%
Shares short (30 Apr 2024) 42.63M
Short ratio (30 Apr 2024) 45.37
Short % of float (30 Apr 2024) 42.39%
Short % of shares outstanding (30 Apr 2024) 42.08%
Shares short (prior month 28 Mar 2024) 42.8M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -16.58%
Operating margin (ttm)-8.79%

Management effectiveness

Return on assets (ttm)-3.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2B
Revenue per share (ttm)15.97
Quarterly revenue growth (yoy)54.80%
Gross profit (ttm)N/A
EBITDA -122.3M
Net income avi to common (ttm)-332.08M
Diluted EPS (ttm)-2.64
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.37B
Total cash per share (mrq)18.75
Total debt (mrq)2.68B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.17
Book value per share (mrq)-1.73

Cash flow statement

Operating cash flow (ttm)189.12M
Levered free cash flow (ttm)172.9M